Simulator-Based assessment of driving performance in patients with Parkinson's disease and multiple sclerosis
NCT ID NCT07809828
First seen Sep 09, 2026 · Last updated Sep 09, 2026
Summary
This prospective observational study investigates whether driving performance measured in a standardized driving simulator differs between people with Parkinson's disease, people with multiple sclerosis, and healthy drivers. Participants will complete a standardized simulated driving assessment designed to evaluate abilities relevant to safe driving, including lane keeping, speed control, vehicle following, responses to hazards, lane changes, navigation, and compliance with traffic rules. Driving simulator measures will also be examined in relation to clinical characteristics and results from previously performed cognitive, motor, and psychodiagnostic assessments in the patient groups. The main research question is whether a driving simulator can detect measurable patterns of driving performance associated with Parkinson's disease or multiple sclerosis when compared with healthy drivers. The study hypothesis is that participants with these neurological conditions will show differences in selected driving performance measures and that some of these differences will be associated with the clinical severity and functional manifestations of their disease. The study will also explore whether additional information from eye tracking, video-based measurements, and physiological signals can improve the characterization of driving performance. The results are intended to support the development of objective methods for studying driving-related functions in neurological disease. Simulator results will be used for research purposes and will not by themselves determine an individual's medical fitness to drive.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 100 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Nov 2026
An estimate. Start dates often move.
- Expected to finish
-
Dec 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
The clinical study population will be drawn from participants previously assessed within the OP-JAK (NCT07360886) research framework at the participating neurological center. These participants have established diagnoses of Parkinson's disease or multiple sclerosis and have previously completed relevant psychodiagnostic and screening assessments. The healthy control group will be recruited separately by the technology partner from the general community and assessed using the same standardized driving simulator protocol under comparable technical and organizational conditions. The study therefore includes two clinically characterized neurological cohorts and one non-clinical community-based control cohort.
- Ages
-
18 to 85 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age 18 to 85 years. * Ability to understand study instructions and provide written informed consent. * Valid driving license for passenger vehicles (Category B or equivalent). * Active non-professional driving of a motor vehicle. * Ability to understand the instructions and complete the standardized driving simulator assessment. For participants with multiple sclerosis: * Confirmed diagnosis of multiple sclerosis according to applicable diagnostic criteria. * Expanded Disability Status Scale (EDSS) score less than 6.5. * Clinically stable disease at the time of simulator assessment. * At least 6 weeks since the most recent multiple sclerosis relapse and any corticosteroid treatment for relapse. * Previous completion of the psychodiagnostic and screening assessment used in the preceding OP-JAK research framework (NCT07360886) within 6 months before simulator testing, provided that no clinically relevant deterioration has occurred. * Completion of the required neurological, ophthalmological, visual-field, and audiometric assessments before or on the day of simulator testing, as specified by the study protocol. For participants with Parkinson's disease: * Confirmed diagnosis of idiopathic Parkinson's disease. * Hoehn and Yahr less than stage IV in the ON-medication state. * Clinically stable condition at the time of simulator assessment. * Ability to undergo simulator testing during the best practically achievable ON-medication state. * Previous completion of the psychodiagnostic and screening assessment used in the preceding OP-JAK research framework within 6 months before simulator testing, provided that no clinically relevant deterioration has occurred. * Completion of the required neurological, ophthalmological, visual-field, and audiometric assessments before or on the day of simulator testing, as specified by the study protocol. For healthy control participants: * No known neurological disorder expected to substantially affect driving performance. * Self-reported current health status compatible with safe completion of the driving simulator assessment. * Visual and auditory function, with usual correction if applicable, sufficient to safely and validly complete the simulator assessment. Exclusion Criteria: * Acute medical or neurological deterioration that would prevent safe or valid completion of the driving simulator assessment. * Current intoxication with alcohol or other psychoactive substances. * Marked sleep deprivation, excessive fatigue, or another temporary condition that, in the judgment of the responsible study personnel, would substantially impair the ability to complete testing safely and validly. * Severe simulator sickness or current vestibular symptoms that prevent completion of simulator testing. * Clinically significant uncorrected visual or auditory impairment that prevents valid completion of the simulator assessment. Inability to understand study instructions or safely operate the driving simulator. \- Withdrawal of consent or refusal of data recording required for the study when no technically valid alternative method is available. Additional exclusion criteria for participants with multiple sclerosis: * Current multiple sclerosis relapse. * Less than 30 days since the most recent relapse or corticosteroid treatment for relapse. * EDSS score \> 6.5. Additional exclusion criteria for participants with Parkinson's disease: * Atypical parkinsonian syndrome. * Hoehn and Yahr stage \> 4 in the ON-medication state. * Deep brain stimulation in the main Parkinson's disease cohort. * Clinical condition preventing testing during a sufficiently stable ON-medication period. Additional exclusion criteria for healthy control participants: * Self-reported neurological disease or other health condition expected to substantially influence cognitive, sensory, or motor functions relevant to driving. * Current psychiatric or medical condition that would prevent safe or valid completion of the simulator assessment. * Current use of substances or medications producing an acute level of impairment incompatible with safe simulator testing.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Multiple sclerosis are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Contrasting chronic inflammation and neurodegeneration using the human amniotic mesenchymal cell secretome as an innovative therapeutic strategy
- VIGIP-SEP2: evaluation of the impact of the training of patients by nurses on the adverse drug reaction reporting by RRMS patient via a mobile application: a randomized real-life study
- Five-second sprints on a bike: a new test for multiple sclerosis symptoms
- A new way to gauge balance training intensity in MS?
- A PET tracer aims to reveal the brain inflammation MRI misses in MS
- Targeting hidden balance issues: a new therapy for early MS